Nutriband CEO Highlights AVERSA™ in Opioid Crisis Documentary
Event summary
- Nutriband CEO Gareth Sheridan featured in Nick Shirley's documentary on America's opioid crisis, released September 29, 2026.
- Sheridan discussed Nutriband's AVERSA™ abuse-deterrent technology as a solution to reduce opioid abuse, misuse, and diversion.
- AVERSA™ is designed to make transdermal patches harder to abuse while maintaining access for legitimate medical use.
- Technology is patented in multiple countries, including the U.S., Europe, and China.
The big picture
Nutriband's participation in the documentary underscores the growing demand for innovative solutions to the opioid crisis. The company's AVERSA™ technology aims to address a critical gap in the market by balancing access for legitimate medical use with abuse prevention. The opioid crisis remains a significant public health challenge, driving regulatory and market interest in technologies like AVERSA™.
What we're watching
- Regulatory Approval
- Whether Nutriband can secure FDA approval for its abuse-deterrent fentanyl patch, a critical step for commercialization.
- Market Adoption
- The pace at which AVERSA™ technology gains acceptance among healthcare providers and patients.
- Competitive Positioning
- How Nutriband differentiates itself in the crowded opioid abuse-deterrent market.
Related topics